¥ 4160
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Strong margins and returns
About
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/
Target Price
The average target price of 4568.T is 5250 and suggests 28% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
